DHCPL for ACE-inhibitor/Angiotensin receptor blocker containing medicines

DHCPL for ACE-inhibitor/Angiotensin receptor blocker containing medicines

In collaboration with the South African Health Products Regulatory Authority (SAHPRA), Novartis SA (Pty) Ltd would like to inform you of a risk of acute kidney injury (AKI) in patients treated concomitantly with Angiotensin Converting Enzyme Inhibitors (ACEIs) /Angiotensin receptor blockers (ARBs) and fluoroquinolones.

2019 Oct

Download latest version
File Type: pdf
Category: Communication To Health Care Professionals
Unit: pharmacovigilance